Last updated: February 27, 2026
What is the drug associated with NDC 69680-0186?
NDC 69680-0186 refers to Xadago (safinamide), used as an adjunct therapy in Parkinson’s disease management. Safinamide is a reversible MAO-B inhibitor approved by the FDA in 2017.
What is the current market landscape?
Market size and demand
- The global Parkinson’s disease market was valued at approximately USD 4.4 billion in 2022.
- The disease prevalence is estimated to be 10 million globally; in the U.S., around 1 million patients are diagnosed.
- Safinamide's market share is confined to the adjunct therapy segment, competing directly with drugs like rasagiline (Azilect) and selegiline.
Key competitors
| Drug Name |
Year Approved |
Mechanism |
Market Share (Estimated) |
Pricing (2023 USD per month) |
| Safinamide |
2017 |
Reversible MAO-B inhibitor |
15-20% |
$500-700 |
| Rasagiline |
2006 |
Irreversible MAO-B inhibitor |
35-40% |
$400-600 |
| Selegiline |
1960 |
Irreversible MAO-B inhibitor |
10-15% |
$200-400 |
Safinamide is positioned as an alternative for patients intolerant to older MAO-B inhibitors.
Market dynamics
- Increasing Parkinson’s disease prevalence drives demand growth.
- Prescription trends favor drugs with improved tolerability and fewer food interactions.
- Existing formulations have pricing pressure from generics; safinamide remains branded, maintaining higher pricing margins.
What are the price projections?
Short-term outlook (2023–2025)
- Current average retail price: USD 500–700 per month.
- Price reductions due to competitive pressure could reduce net prices to USD 450–600 by 2025.
- Anticipated discounts and rebates may lower net prices further.
- No significant price erosion expected within initial patent exclusivity period; generics unlikely before 2027.
Mid-term outlook (2026–2030)
- Patent expiry anticipated around 2027, opening market to generics.
- Generic safinamide expected to launch at 50-70% of branded prices, i.e., USD 200–350 per month.
- Post-patent landscape would reduce overall market prices, impacting revenue per unit but potentially expanding the patient pool due to affordability.
Revenue implications
| Scenario |
Year |
Estimated Annual Revenue (USD millions) |
Assumptions |
| Base Case |
2024 |
150–200 |
Sustained pricing, moderate market share |
| Conservative |
2027 |
50–75 |
Patent expiry, generic entry, market share decline |
| Optimistic |
2030 |
100–150 |
Expanded indications or formulations |
What regulatory and market factors influence pricing?
- Patent protection: Expires around 2027 in key markets (U.S., EU).
- Market access and reimbursement policies: Payers are increasingly favoring cost-effective generics.
- Pricing regulations: Countries like Canada and those in Europe enforce price controls.
- Market penetration: Adoption depends on physician preferences, clinical data, and formulary inclusion.
What risks influence future market sizing and pricing?
- Introduction of biosimilars or new classes of Parkinson’s treatments.
- Changes in regulatory policies affecting exclusivity.
- Patent litigation or challenges.
- Slow adoption, due to either clinical preferences or insurance barriers.
Key Takeaways
- NDC 69680-0186 (safinamide) operates in a competitive, growing Parkinson’s disease market.
- Pricing is currently stable at USD 500–700/month, with potential reductions post-2027 due to patent expiration.
- Revenue prospects depend on market penetration, evolving generics landscape, and regional reimbursement policies.
- Patent expiry around 2027 marks the transition point for generic entry and significant price erosion.
- Market dynamics favor early adoption of branded safinamide for its tolerability and clinical benefits.
FAQs
Q1: When will generic safinamide likely enter the market?
A1: Based on current patent timelines, late 2026 or early 2027, assuming patent protections are maintained without legal challenges.
Q2: How does safinamide compare to other MAO-B inhibitors in terms of efficacy?
A2: Clinical trials show comparable efficacy to rasagiline, with some evidence suggesting better tolerability and fewer drug interactions.
Q3: Are there off-label uses for safinamide?
A3: Currently, safinamide is approved solely for Parkinson’s disease; off-label applications are limited and not broadly recognized.
Q4: What is the potential for market expansion beyond Parkinson’s?
A4: Limited, as safinamide’s indication is confined; research into other neurodegenerative disorders is ongoing but unapproved.
Q5: How do reimbursement policies impact safinamide's market outlook?
A5: Favorable coverage accelerates adoption; restrictive policies or high out-of-pocket costs slow growth, particularly in Europe and emerging markets.
Citations:
- Grand View Research. (2022). Parkinson’s Disease Market Size, Share & Trends Analysis.
- U.S. Food and Drug Administration. (2017). FDA approves Xadago to treat Parkinson’s disease.
- IQVIA. (2023). Pharmaceutical Market Data Report.
